Core Insights - AxoGen, Inc. specializes in developing and marketing surgical solutions for peripheral nerve injuries, operating in the healthcare sector with a focus on nerve repair and protection [1] - The company faces competition from AtriCure, Tactile Systems Technology, BioLife Solutions, AnaptysBio, and Assembly Biosciences [1] Financial Performance - AxoGen's Return on Invested Capital (ROIC) is 2.07%, which is significantly lower than its Weighted Average Cost of Capital (WACC) of 8.72%, indicating inefficient capital utilization [2][5] - AtriCure has a negative ROIC of -6.47% and a WACC of 11.01%, resulting in a ROIC to WACC ratio of -0.59, suggesting struggles in generating returns above its cost of capital [3] - BioLife Solutions and AnaptysBio also report negative ROICs of -4.85% and -28.56%, respectively, with WACCs of 12.57% and 9.10% [3] - Assembly Biosciences shows the highest inefficiency with a ROIC of -127.67% and a WACC of 6.45%, leading to a ROIC to WACC ratio of -19.80 [4][5]